DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
DiaMedica Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$7.87+0.30 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $424.15M
- P/E (TTM)
- –
- Dividend yield
- –
DiaMedica Therapeutics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -67.7%
Financial strength
- Current ratio
- 6.72
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 77.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 11.06
- Dividend yield
- –